Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Chien · SciRah

Researcher profile · Semantic Scholar

J. Chien

Share profile

J. Chien — researcher profile on SciRah

h-index: 28
Works: 164
Citations: 4,710

Most-cited papers

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases
N. Lin, R. Murthy, V. Abramson, C. Anders +23 more
2022JAMA Oncology184 citations Open access
Semantic Scholar
The clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
M. Magbanua, L. Brown-Swigart, Ziad Ahmed, R. Sayaman +27 more
2023Cancer Cell169 citations Open access
Semantic Scholar
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
A. Clark, C. Yau, D. Wolf, E. Petricoin +47 more
2021Nature Communications73 citations Open access
Semantic Scholar
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
L. Huppert, R. Mahtani, Samantha Fisch, Naomi Dempsey +18 more
2025npj Breast Cancer64 citations Open access
Semantic Scholar
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomised I-SPY2.2 phase 2 trial
R. Shatsky, M. Trivedi, C. Yau, Rita Nanda +56 more
2024Nature Medicine55 citations Open access
Semantic Scholar
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
A. Wardley, J. Cortés, L. Provencher, K. Miller +18 more
2021Breast Cancer Research and Treatment26 citations Open access
Semantic Scholar
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
J. Lang, A. Forero-Torres, D. Yee, C. Yau +45 more
2022npj Breast Cancer23 citations Open access
Semantic Scholar
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
A. Chan, M. Ruíz-Borrego, G. Marx, J. Chien +18 more
2022Breast23 citations Open access
Semantic Scholar
Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial
J. Letourneau, Flor Juarez-Hernandez, Kaitlyn Wald, S. Ribeiro +7 more
2021Journal of Assisted Reproduction and Genetics20 citations Open access
Semantic Scholar
Datopotamab-deruxtecan in early stage breast cancer: the I-SPY2.2 sequential multiple assignment randomized phase 2 trial
Katia Khoury, J. Meisel, C. Yau, H. Rugo +53 more
2024Nature Medicine17 citations Open access
Semantic Scholar
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
Harriet T. Rothschild, Elle N. Clelland, Anne Patterson, Julissa Molina-Vega +5 more
2023Breast Cancer Research and Treatment16 citations Open access
Semantic Scholar
The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
M. K. Abel, Amy S. Shui, J. Chien, H. Rugo +3 more
2022Annals of Surgical Oncology15 citations Open access
Semantic Scholar
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial — Efficacy and biomarker discovery
K. Albain, C. Yau, E. F. Petricoin, D. Wolf +45 more
2023Clinical Cancer Research14 citations Open access
Semantic Scholar
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study
L. Huppert, Zak Walker, Mo-Ming Li, Mi-Ok Kim +7 more
2022Breast Cancer Research and Treatment14 citations
Semantic Scholar
Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
C. Isaacs, R. Nanda, J. Chien, M. Trivedi +31 more
2023Cancer Research13 citations
Semantic Scholar
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
H. Beckwith, Richard B. Schwab, C. Yau, E. Stringer-Reasor +28 more
2021Poster Spotlight Session Abstracts13 citations
Semantic Scholar
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Beverly Kyalwazi, C. Yau, Michael J. Campbell, T. Yoshimatsu +30 more
2023JAMA Network Open12 citations Open access
Semantic Scholar
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Helena Record, Elle N. Clelland, Harriet T. Rothschild, M. Kaur +6 more
2023npj Breast Cancer12 citations Open access
Semantic Scholar
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
M. K. Abel, M. Melisko, H. Rugo, J. Chien +7 more
2021npj Breast Cancer11 citations Open access
Semantic Scholar
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial
R. Mukhtar, K. Dimitroff, C. Yau, J. Chien +32 more
2025Annals of Surgical Oncology10 citations
Semantic Scholar
Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting
Neel D. Pasricha, Stella K. Kim, Asim V. Farooq, Ethan S. Lindgren +22 more
2025JAMA ophthalmology10 citations
Semantic Scholar
Impact of Systemic Therapy on Fertility in Women with Early-Stage Breast Cancer
K. Natsuhara, J. Chien
2024Current Breast Cancer Reports10 citations Open access
Semantic Scholar
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
K. Natsuhara, Kelly Blum, A. LeVee, Nikitha Vobugari +16 more
2025Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
L. Huppert, R. Mahtani, Samantha Fisch, Naomi Dempsey +15 more
2024Cancer Research9 citations
Semantic Scholar
Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes
Elle N. Clelland, Harriet T. Rothschild, Anne Patterson, Julissa Molina-Vega +6 more
2023Breast Cancer Research and Treatment9 citations Open access
Semantic Scholar
Emerging immunotherapeutic strategies for the treatment of breast cancer
L. Huppert, V. Mariotti, J. Chien, H. Soliman
2021Breast Cancer Research and Treatment9 citations
Semantic Scholar
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
H. Rugo, Mike Campbell, C. Yau, J. Chien +19 more
2024Breast Cancer Research and Treatment8 citations Open access
Semantic Scholar
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy
Saya Jacob, A. Christofferson, Samantha Fisch, P. Norwood +13 more
2024Breast Cancer Research and Treatment6 citations Open access
Semantic Scholar
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
D. Wolf, C. Yau, M. Campbell, A. Glas +31 more
2025JCO Precision Oncology5 citations Open access
Semantic Scholar
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early-stage breast cancer: the I-SPY SURMOUNT Study
M. Magbanua, L. J. van 't Veer, A. Clark, J. Chien +23 more
2023Breast Cancer Research and Treatment5 citations Open access
Semantic Scholar
The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB)
Harriet T. Rothschild, Elle N. Clelland, M. K. Abel, J. Chien +4 more
2023Breast Cancer Research and Treatment5 citations Open access
Semantic Scholar
Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer
J. Chien, K. Kalinsky, Julissa Molina-Vega, R. Mukhtar +14 more
2022Cancer Research5 citations
Semantic Scholar
Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions
R. Mukhtar, J. Chien
2021Current Breast Cancer Reports5 citations Open access
Semantic Scholar
Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer
Saya Jacob, Samantha Fisch, Carolyn Face, Kelly Blum +16 more
2025npj Breast Cancer4 citations Open access
Semantic Scholar
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer
S. Umashankar, Mo-Ming Li, Kaylee Blevins, Mi-Ok Kim +7 more
2024Breast Cancer Research and Treatment4 citations Open access
Semantic Scholar
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Beverly Kyalwazi, C. Yau, O. Olopade, J. Chien +32 more
2022Cancer Research4 citations
Semantic Scholar
A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy
K. Switalla, N. Onishi, Ella F. Jones, Courtney Lawhn-Heath +18 more
2026Breast Cancer Research3 citations Open access
Semantic Scholar
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer
L. Huppert, Amelia S Gliwa, Madeline Tait, L. Quintal +10 more
2025npj Breast Cancer3 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
S. Alkhafaji, M. Magbanua, L. J. van 't Veer, K. Giridhar +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
R. Mukhtar, K. Dimitroff, C. Yau, L. J. van 't Veer +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL
D. Wolf, C. Yau, M. Campbell, H. Soliman +14 more
2022Cancer Research3 citations
Semantic Scholar
Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer.
Nikita V. Baclig, Madhuri Chengappa, A. Soliman, Saya Jacob +18 more
2026Clinical Breast Cancer2 citations Open access
Semantic Scholar
Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
E. Stringer-Reasor, R. Shatsky, J. Chien, A. Wallace +27 more
2023Cancer Research2 citations
Semantic Scholar
Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer
A. Chan, M. Ruíz-Borrego, G. Marx, A. Brufsky +14 more
2022Cancer Research2 citations
Semantic Scholar
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
J. Chien, Beverly Kyalwazi, L. Esserman
2022Cell Reports Medicine2 citations Open access
Semantic Scholar
Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer
M. Ruíz-Borrego, A. Chan, G. Marx, A. Brufsky +12 more
20212 citations
Semantic Scholar
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
S. Modi, R. Murthy, J. Chien, N. Lin +9 more
2026Clinical Breast Cancer1 citations Open access
Semantic Scholar
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study
Nira A. Krasnow, Michelle Jayaraj, M. Salans, Kelsey Kuwahara +13 more
2025Breast Cancer Research1 citations Open access
Semantic Scholar
Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
J. Hilton, K. Jerzak, J. Chien, José Luiz Miranda Guimarães +8 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract PO4-12-06: Interstitial Lung Disease (ILD) in Sequential Antibody Drug Conjugate (ADC) use in patients with Metastatic Breast Cancer (MBC): A Multi-Institutional experience
S. Premji, L. Huppert, R. Mahtani, Samantha Fisch +15 more
2024Cancer Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Rugo×32
Invite
H. Rugo — researcher profile on SciRah
M. Melisko×19
Invite
M. Melisko — researcher profile on SciRah
W. Symmans×16
Invite
W. Symmans — researcher profile on SciRah
A. DeMichele×16
Invite
A. DeMichele — researcher profile on SciRah

×16

Invite

L. Huppert — researcher profile on SciRah

Invite

C. Yau — researcher profile on SciRah

L. Esserman×15

Invite

L. Esserman — researcher profile on SciRah

L. J. van 't Veer×15

Invite

L. J. van 't Veer — researcher profile on SciRah

Invite

G. Hirst — researcher profile on SciRah

J. Perlmutter×14

Invite

J. Perlmutter — researcher profile on SciRah

Invite

S. Asare — researcher profile on SciRah

Invite

R. Mukhtar — researcher profile on SciRah